WO2014025199A3 - 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 - Google Patents

스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 Download PDF

Info

Publication number
WO2014025199A3
WO2014025199A3 PCT/KR2013/007112 KR2013007112W WO2014025199A3 WO 2014025199 A3 WO2014025199 A3 WO 2014025199A3 KR 2013007112 W KR2013007112 W KR 2013007112W WO 2014025199 A3 WO2014025199 A3 WO 2014025199A3
Authority
WO
WIPO (PCT)
Prior art keywords
seb
mutant
target
modified
fusion protein
Prior art date
Application number
PCT/KR2013/007112
Other languages
English (en)
French (fr)
Other versions
WO2014025199A2 (ko
Inventor
장우익
배진건
조영규
원재선
양인영
윤창현
부경현
이운영
이진각
이민경
Original Assignee
주식회사 한독
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020130089540A external-priority patent/KR20140021485A/ko
Application filed by 주식회사 한독 filed Critical 주식회사 한독
Publication of WO2014025199A2 publication Critical patent/WO2014025199A2/ko
Publication of WO2014025199A3 publication Critical patent/WO2014025199A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

본원은 변형된 SEB(staphylococcal Enterotoxin B), 이를 코딩하는 폴리뉴클레오타이드, 이를 포함하는 벡터 및 숙주세포가 개시된다. 본원은 또한 본원에 따른 변형된 SEB 또는 야생형 SEB 및 이와 융합된 표적 특이적 폴리펩타이드의 융합단백질 및 이의 질환 치료제로서의 용도가 개시된다. 본원에 개시된 SEB 변이체 및 이를 포함하는 융합단백질은 특정 세포를 특이적으로 인식할 수 있도록 제조되어 면역계 활성화를 통해 암과 같은 특정 세포의 사멸을 유도하여 질환의 치료에 유용하게 이용될 수 있다.
PCT/KR2013/007112 2012-08-09 2013-08-07 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 WO2014025199A2 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2012-0087478 2012-08-09
KR20120087478 2012-08-09
KR10-2013-0089540 2013-07-29
KR1020130089540A KR20140021485A (ko) 2012-08-09 2013-07-29 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도

Publications (2)

Publication Number Publication Date
WO2014025199A2 WO2014025199A2 (ko) 2014-02-13
WO2014025199A3 true WO2014025199A3 (ko) 2014-04-03

Family

ID=50068657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/007112 WO2014025199A2 (ko) 2012-08-09 2013-08-07 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도

Country Status (1)

Country Link
WO (1) WO2014025199A2 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
CN104974261B (zh) * 2014-04-01 2019-06-14 三生国健药业（上海）股份有限公司 重组抗her2/ps双特异性抗体、其制备方法和应用
WO2017120589A1 (en) * 2016-01-08 2017-07-13 Washington University Compositions comprising chemerin and methods of use thereof
CN107236046B (zh) * 2017-05-15 2021-05-07 江苏吴中医药集团有限公司苏州中凯生物制药厂 一种重组人内皮抑素融合蛋白及其制备方法和应用
EP3746459A1 (en) * 2018-02-02 2020-12-09 Univerza V Ljubljani Affinity ligands for antibody fc region
CN114848794A (zh) * 2022-05-25 2022-08-05 沈阳协合生物制药股份有限公司 一种通过调节t细胞免疫预防和治疗骨质疏松病的方法
CN116284448A (zh) * 2023-02-14 2023-06-23 浙江大学 一种超抗原参与的三功能t细胞衔接器及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US20050260215A1 (en) * 1994-07-11 2005-11-24 Lars Abrahmsen Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
US20060024322A1 (en) * 1998-02-15 2006-02-02 Juridical Foundation The Chemo-Sero-Therapeutic Research And Kowa Company, Ltd. Novel prophylactics/remedies for immunopathy
US20060052295A1 (en) * 2002-05-08 2006-03-09 Terman David S Intrathecal and intratumoral superantigens to treat malignant disease
US8226958B2 (en) * 2003-03-28 2012-07-24 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Modified SEB and prophylactics/remedies for immunopathy containing the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
US20050260215A1 (en) * 1994-07-11 2005-11-24 Lars Abrahmsen Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
US20060024322A1 (en) * 1998-02-15 2006-02-02 Juridical Foundation The Chemo-Sero-Therapeutic Research And Kowa Company, Ltd. Novel prophylactics/remedies for immunopathy
US20060052295A1 (en) * 2002-05-08 2006-03-09 Terman David S Intrathecal and intratumoral superantigens to treat malignant disease
US8226958B2 (en) * 2003-03-28 2012-07-24 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Modified SEB and prophylactics/remedies for immunopathy containing the same

Also Published As

Publication number Publication date
WO2014025199A2 (ko) 2014-02-13

Similar Documents

Publication Publication Date Title
WO2014025199A3 (ko) 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014025198A3 (ko) Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
TWI799368B (zh) 抗ｔｌ１ａ抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
WO2014200910A3 (en) Bioinformatic processes for determination of peptide binding
WO2014145016A3 (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
TN2014000536A1 (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
TN2015000085A1 (en) Fc containing polypeptides with altered glycosylation and reduced effector function
TW201613954A (en) Interleukin-10 fusion proteins and uses thereof
WO2013184939A3 (en) Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
NZ719654A (en) Interleukin-2 fusion proteins and uses thereof
WO2014011901A3 (en) Methods and compositions for delivery of biologics
MX2019009191A (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas.
MX348071B (es) Variantes de fc.
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
TN2012000167A1 (en) Human il-23 antigen binding proteins
GB201008682D0 (en) Epitope tag for affinity based applications
WO2014005683A8 (en) Dna vaccine for use in pancreatic cancer patients
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
MD20140104A2 (ro) Polipeptide care se leagă de CX3CR1
MX2016002166A (es) Anticuerpos.
CY1121795T1 (el) Αντισωματα κατα toy cd52
MX356162B (es) Sistema de expresion y secrecion.
EP3180463A4 (en) Detecting residual host cell proteins in recombinant protein preparations

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13828513

Country of ref document: EP

Kind code of ref document: A2